Mr. Rene Goehrum reports

BIOSYENT RELEASES Q2 AND SIX MONTH RESULTS-Q2 SALES INCREASE 72%, NET INCOME AFTER TAX UP 112%

BioSyent Inc. has released its second quarter (Q2 2014) and first half (H1 2014) financial results for the three and six months ending June 30, 2014. Key highlights include:

• Q2 2014 sales of $3,072,395 increased by 72 per cent versus Q2 2013;
• First six months (H1 2014) sales of $5,520,496 increased by 66 per cent versus H1 2013;
• Q2 2014 revenue has grown at a compound annual growth rate (CAGR) of 68 per cent over the corresponding quarters of the last three years;
• First six months (H1 2014) revenue has grown at a compound annual growth rate (CAGR) of 70 per cent over the corresponding three-year period;
• Q2 2014 pharmaceutical sales of $2,893,162 were up 72 per cent versus Q2 2013;
• H1 2014 pharmaceutical sales of $5,236,170 increased by 75 per cent versus H1 2013;
• Nineteen consecutive quarters of continued pharmaceutical sales growth;
• Q2 2014 net income before tax of $1,219,855 increased by 125 per cent versus Q2 2013;
• H1 2014 net income before tax of $1,907,527 increased by 86 per cent versus $1,024,927 in H1 2013;
• Q2 2014 net income after tax of $888,805 increased by 112 per cent versus Q2 2013;
• H1 2014 net income after tax of $1,400,226 increased by 84 per cent versus H1 2013;
• Q2 2014 diluted earnings per share of six cents versus three cents in Q2 2013;
• Trailing 12-month (TTM) fully diluted EPS of 18 cents;
• The company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada;
• New urgent care product received Health Canada marketing approval in Q2 2014;
• Launched new women's health product, RepaGyn, in Q2 2014;
• Prelaunch activity for a new gastrointestinal health product -- launch planned for fourth quarter of 2014;
• In July, BioSyent in-licensed a third new urgent care drug product from the same European partner;
• Selected as a TSX Venture 50 top performer for three consecutive years -- 2012, 2013 and 2014;
• For the second consecutive year BioSyent named as one of Canada's fastest-growing companies in the Profit 500 rankings with a five-year growth rate of 608.

Total sales for Q2 2014 of $3,072,395 were 72 per cent higher compared with $1,786,684 in the corresponding prior year period. Total sales for H1 2014 of $5,520,496 were 66 per cent higher than H1 2013.

Pharmaceutical sales in Q2 2014 increased by 72 per cent from $1,683,793 in Q2 2013 to $2,893,162 in Q2 2014. Total pharmaceutical sales for H1 2014 of $5,236,170 were 75 per cent higher than H1 2013.

Net income before tax for Q2 2014 was $1,219,855, which was 125 per cent higher than $542,964 in Q2 2013. Net income before tax for H1 2014 was $1,907,527, or 86 per cent higher than the corresponding prior year period.

Net income after tax increased by 112 per cent from $418,325 in Q2 2013 to $888,805 in Q2 2014. Net income after tax for H1 2014 was $1,400,226, or 84 per cent higher than the corresponding prior year period.

Basic and diluted earnings per share were six cents in Q2 2014 versus three cents in Q2 2013. H1 2014 basic EPS was 10 cents versus six cents in H1 2013. Diluted EPS in H1 2014 was 10 cents versus five cents in H1 2013.

Working capital, which is the difference between current assets and current liabilities, increased by 34 per cent from $4,405,910 as at Dec. 31, 2013, to $5,890,238 as at June 30, 2014. Total cash included in working capital on June 30, 2014, is $4,830,796. Total shareholder's equity increased by 31 per cent from $4,854,630 at Dec. 31, 2013, to $6,337,976 at June 30, 2014.

The company plans to launch a new gastrointestinal product in the fourth quarter of 2014. The company also received Health Canada approval on one of its two urgent care products and is planning to launch the product in late 2014 or early 2015.

On July 23, 2014, BioSyent Pharma in-licensed a third urgent care product from an existing European partner. This product will be launched after Health Canada approval.

The company's consolidated financial statements and management's discussion and analysis will be posted on SEDAR on Aug. 21, 2014.

                              
    INTERIM UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME      
                                                                           
                         Q2 2014      Q2 2013       H1 2014      H1 2013

Revenues              $3,072,395   $1,786,685    $5,520,496   $3,328,528
Cost of goods sold       633,754      387,337     1,173,278      695,806
Gross profit           2,438,641    1,399,348     4,347,218    2,632,722
Total operating
Expense                1,218,786      856,384     2,439,691    1,607,795
Profit before tax      1,219,855      542,964     1,907,527    1,024,927
Tax (including
deferred tax)            331,050      124,639       507,301      262,192
Profit after tax         888,805      418,325     1,400,226      762,735
Profit after tax % to
sales                         29%          23%           25%          23%